EP1653977A2 - Behandlung von erkrankungen im zusammenhang mit natürlichen killer-t-zellen - Google Patents

Behandlung von erkrankungen im zusammenhang mit natürlichen killer-t-zellen

Info

Publication number
EP1653977A2
EP1653977A2 EP04778424A EP04778424A EP1653977A2 EP 1653977 A2 EP1653977 A2 EP 1653977A2 EP 04778424 A EP04778424 A EP 04778424A EP 04778424 A EP04778424 A EP 04778424A EP 1653977 A2 EP1653977 A2 EP 1653977A2
Authority
EP
European Patent Office
Prior art keywords
cells
beta
galactosyl ceramide
subject
cdld
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04778424A
Other languages
English (en)
French (fr)
Inventor
John Ortaldo
Robert Wiltrout
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of EP1653977A2 publication Critical patent/EP1653977A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP04778424A 2003-07-17 2004-07-16 Behandlung von erkrankungen im zusammenhang mit natürlichen killer-t-zellen Withdrawn EP1653977A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48833903P 2003-07-17 2003-07-17
PCT/US2004/022913 WO2005014008A2 (en) 2003-07-17 2004-07-16 Treatment of disorders associated with natural killer t cells

Publications (1)

Publication Number Publication Date
EP1653977A2 true EP1653977A2 (de) 2006-05-10

Family

ID=34135090

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04778424A Withdrawn EP1653977A2 (de) 2003-07-17 2004-07-16 Behandlung von erkrankungen im zusammenhang mit natürlichen killer-t-zellen

Country Status (2)

Country Link
EP (1) EP1653977A2 (de)
WO (1) WO2005014008A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE536185T1 (de) 2001-03-26 2011-12-15 Dana Farber Cancer Inst Inc Verfahren zur abschwächung von reaktionen auf hautreizende mittel
PT1812015E (pt) 2004-11-02 2012-02-20 Univ Leland Stanford Junior Métodos de inibição de células nkt
WO2006122296A1 (en) * 2005-05-11 2006-11-16 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Isolation and structure of turbostatins 1-4
IL172175A0 (en) * 2005-11-24 2011-08-01 Hadasit Med Res Service Beta glycolipids as immuno-modulators
US10045953B2 (en) 2006-07-06 2018-08-14 Case Western Reserve University Ceramide composition and method of use
US8835613B2 (en) * 2010-03-12 2014-09-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services β-mannosylceramide and stimulation of NKT cell anti-tumor immunity
GB201517859D0 (en) * 2015-10-08 2015-11-25 Altermune Ltd Novel compounds and therapeutic uses thereof
EP3777891A4 (de) * 2018-03-29 2022-03-23 Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences Künstlich synthetisiertes sphingosinderivat-lipoidmonomer und dessen verwendung zur verabreichung von nukleinsäure
EP3820994A1 (de) * 2018-07-10 2021-05-19 Nantkwest, Inc. Erzeugung von cik-nkt-zellen aus nabelschnurblut
CN110776544B (zh) * 2019-11-11 2023-03-10 三峡大学 一类2,3-不饱和半乳糖硫苷类化合物及其合成方法
WO2024002746A1 (en) * 2022-07-01 2024-01-04 Evonik Operations Gmbh Compositions comprising self tanning agents and certain sphingolipids and/or certain sphingoid bases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63255213A (ja) * 1987-04-13 1988-10-21 Kanebo Ltd 養毛化粧料
JPH0317020A (ja) * 1989-06-14 1991-01-25 Nippon Koutai Kenkyusho:Kk 抗ｈｉｖ剤
WO1992017189A1 (en) * 1991-03-29 1992-10-15 The Regents Of The University Of California Gangliosides with immunosuppressive activity
JP2001527046A (ja) * 1997-12-30 2001-12-25 エイプラス サイエンス インベスト アーベー ガラクトシルセラミド、グルコシルセラミド、ラクトシルセラミド、並びに前糖尿病、糖尿病および／または関連合併症の予防もしくは治療に使用するためのその特定キャッチャー
WO1999041266A1 (en) * 1998-02-12 1999-08-19 Emory University Sphingolipid derivatives and their methods of use
JP2000264825A (ja) * 1999-03-17 2000-09-26 Fancl Corp 乳化組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005014008A2 *

Also Published As

Publication number Publication date
WO2005014008A3 (en) 2005-11-03
WO2005014008A2 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
AU2018372167B2 (en) Partial agonists of interleukin-2
Shalaby et al. The involvement of human tumor necrosis factors-alpha and-beta in the mixed lymphocyte reaction.
SK21195A3 (en) Pharmaceutical substance containing il-4 and/or il-10 or antibodies against il-4 and il-10, method of manufacture and use thereof
DE69834330T2 (de) Verwendung von mhc klasse ii liganden als adjuvantien zur impfung und von lag-3 zur krebstherapie
KR20050109928A (ko) 유산균으로부터 유래된 소염 활성
US20180021401A1 (en) Compositions and methods for treatment of intracellular damage and bacterial infection
JP2002515247A (ja) Ｉｌ−２の選択的アゴニスト及びアンタゴニスト
JP6682438B2 (ja) 癌治療のための改善された細胞組成物および方法
KR101521197B1 (ko) 병용 요법에 있어서 ｃｄ83의 용도
Richards et al. Use of human prolactin as a therapeutic protein to potentiate immunohematopoietic function
AU2001261585A1 (en) Compositions and methods for achieving immune suppression
WO2001087330A2 (en) Compositions and methods for achieving immune suppression
WO2005014008A2 (en) Treatment of disorders associated with natural killer t cells
WO2020232427A2 (en) Therapeutic compositions and methods for treating cancer in combination with analogs of interleukin proteins
KR20100109099A (ko) 암 특이 면역반응 유도능을 갖는 수지상 세포의 제조 방법,이 수지상 세포를 포함하는 암의 예방, 치료, 또는 전이 억제용 약제학적 조성물 및 키트
KR101723786B1 (ko) Ｉｌ―２１을 발현하는 중간엽 줄기세포를 포함하는 ｂ 세포 림프종 예방 또는 치료용 조성물
JP5954174B2 (ja) 免疫誘導剤
JP5954175B2 (ja) 免疫誘導剤
JPH11510806A (ja) 免疫抑制治療のためのインターロイキン１０およびシクロスポリンの併用
EP3313429B1 (de) Immunmodulation zur langfristigen vorbeugung und behandlung von autoimmunkrankheiten und fremdgewebeabstossung
Redlinger Jr et al. Advanced neuroblastoma impairs dendritic cell function in adoptive immunotherapy
KR102520880B1 (ko) 면역유도제
RU2233881C2 (ru) Средства и способ получения гемопоэтического белка
Wolfe Tumor necrosis therapy–interleukin-12 fusion proteins and cancer therapy
Frasca et al. Activation of gp130 signaling in vivo by the IL‐6 super‐agonist K‐7/D‐6 accelerates repopulation of lymphoid organs after irradiation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

17P Request for examination filed

Effective date: 20060503

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20070502

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20151013